Autopsy report · NCT02366663

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

“Withdrawal of sponsor support”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 9 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

City of Hope Medical Center

Sponsor type

University, hospital or other

Conditions

Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma

Interventions

90-Yttrium Ibritumomab tiuxetan; Carmustine; Etoposide; Cytarabine; Melphalan; Autologous Hematopoietic Stem Cell Transplant

Participants

3

Sites

2

Countries

United States

Trials that died the same way

• Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
  “sponsor withdrew support” (93% match in meaning)
• Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism
  “Withdrawal of sponsorship” (89% match in meaning)
• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (87% match in meaning)
• Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
  “Withdrawn by Sponsor” (86% match in meaning)
• Study of Regional Cerebral Oxygenation and Brain Blood Volume Changes During Carotid Endarterectomy Using the NeurOS System
  “sponsor withdrew” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.